Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older of any gender.
• People whose ability to carry out daily activities is not severely limited by their illness (based on a standard medical scale called ECOG, a score of 2 or below is required).
• People with an advanced, spread, or inoperable solid tumour that has come back or worsened after at least one previous treatment.
• People who have already received standard treatments known to help their type of cancer, or who have formally declined those treatments in writing.
• People whose tumour has a specific genetic change (such as BRAF, BRCA, EGFR, or ALK) who have already received targeted treatment for that change, or who have formally declined it in writing.
• People whose most recent treatment included a type of immunotherapy drug called an anti-PD-(L)1 medication.
• People whose cancer did not respond to, or came back within 12 months of starting, their most recent treatment (which must have included an anti-PD-(L)1 drug), after at least two rounds of that treatment.
• People with one of the following cancer types: head and neck cancer (squamous cell carcinoma of the mouth, voice box, nasopharynx, or similar areas), malignant melanoma, small cell carcinoma (in the chest or elsewhere in the body), or non-small cell lung cancer.
• People whose cancer can be measured on scans to allow tracking of changes during the trial.
• People with a sufficient number of a specific type of immune cell (lymphocytes) in their blood to potentially allow production of the trial treatment (at least 300 cells per microlitre).
• People who are at least two weeks past their last chemotherapy, major surgery, radiation treatment, or participation in another trial.
• People who have recovered sufficiently from side effects of previous treatments (side effects must be at a low or manageable level on a standard medical scale).
• People whose heart pumping function is within an acceptable range (at least 40% on a standard heart function test).
• People whose kidneys are filtering at an adequate rate (confirm with trial site for exact measurement).
• People whose liver enzyme levels (AST and ALT) are within an acceptable range on blood tests.
• People with adequate levels of immune cells called neutrophils in their blood (at least 1,500 cells per microlitre).
• People with an adequate platelet count in their blood (at least 100,000 cells per microlitre).
• People with an adequate haemoglobin level (at least 8 grams per microlitre).
• People with adequate bilirubin levels in their blood, unless any elevation is due to a harmless inherited condition called Gilbert's disease.
• People with adequate lung function based on a breathing test (at least 50% on a specific measure called corrected DLCO).
• People with no history of abnormal bleeding, inherited clotting disorders, or internal bleeding.
• People who are willing and able to give written consent to take part, with the understanding that they may withdraw at any time without affecting their future care.

Who may not be able to join:

• People who have another active cancer, other than a common type of non-serious skin cancer (non-melanoma skin cancer).
• People whose life expectancy is estimated to be less than 4 months.
• People who test positive for HIV, hepatitis B, or hepatitis C, unless those conditions are stable and well managed with treatment.
• People with high blood pressure that is not adequately controlled.
• People who have had a stroke within the 6 months before joining the trial.
• People who have had a heart attack within the 6 months before joining the trial.
• People with moderate to severe heart failure (classified as NYHA class III or IV).
• People with uncontrolled chest pain or heart disease related to reduced blood supply to the heart.
• People whose cancer has spread to the brain or spinal cord, unless that spread has already been adequately treated.
• People who are pregnant or breastfeeding.
• People of childbearing potential, or males whose partner could become pregnant, who are not willing to use contraception during the trial.
• People who the trial's lead doctor determines should not participate due to unacceptable medical or psychiatric risk.

Important: Always verify eligibility with the trial site directly before applying.